Skip to main content
ANTX
NASDAQ Life Sciences

AN2 Therapeutics 计划为口服 Epetraborole 进行 2 期研究以治疗真性红细胞增多症

feedReported by Reuters
Sentiment info
Positive
Importance info
7
Price
$1.13
Mkt Cap
$29.046M
52W Low
$1
52W High
$1.55
Market data snapshot near publication time

summarizeSummary

AN2 Therapeutics 宣布计划将其口服药物 epetraborole 推进到 2 期临床研究，以治疗真性红细胞增多症 (PV)。这一新适应症代表着该药物潜在市场的重大扩张，超出了其当前为非结核分枝杆菌 (NTM) 疾病而开发的范围。对于一家小盘生物技术公司来说，将药物推进到 2 期是一个重要的降风险事件，也是其开发流水线中的一个关键里程碑。预计 2 期研究将于 2026 年第三季度开始，最初的数据读数预计将于 2026 年第四季度和 2027 年全年公布。投资者将密切关注研究的启动和随后的数据发布作为潜在的催化剂。

在该公告发布时，ANTX的交易价格为$1.13，交易所为NASDAQ，所属行业为Life Sciences，市值约为$2904.6万。 52周交易区间为$1.00至$1.55。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed ANTX - Latest Insights

ANTX
Apr 22, 2026, 4:01 PM EDT
Filing Type: DEF 14A
Importance Score:
8
AN2 Therapeutics Details Highly Dilutive $40M PIPE at Deep Discount and Reprices Executive/Director Options
Sentiment: Negative
View Wiseek Article
ANTX
Apr 20, 2026, 4:33 PM EDT
Filing Type: 424B3
Importance Score:
8
AN2 Therapeutics Registers 14M Shares for Resale by Investors, Creating Significant Stock Overhang
Sentiment: Negative
View Wiseek Article
ANTX
Apr 20, 2026, 4:32 PM EDT
Filing Type: 424B5
Importance Score:
8
AN2 Therapeutics Finalizes $80M At-The-Market Offering, Enabling Substantial Dilution
Sentiment: Negative
View Wiseek Article
ANTX
Apr 09, 2026, 5:21 PM EDT
Filing Type: S-3
Importance Score:
9
AN2 Therapeutics Files S-3 for $300M Universal Shelf, $80M ATM, and Resale of 14M Shares
Sentiment: Negative
View Wiseek Article
ANTX
Apr 09, 2026, 5:03 PM EDT
Filing Type: 8-K
Importance Score:
8
AN2 Therapeutics Establishes New $80M At-The-Market Offering, Replacing Prior Program
Sentiment: Negative
View Wiseek Article
ANTX
Mar 20, 2026, 4:37 PM EDT
Filing Type: 8-K
Importance Score:
8
AN2 Therapeutics Reprices Executive Stock Options to Current Market Price
Sentiment: Negative
View Wiseek Article
ANTX
Mar 17, 2026, 4:03 PM EDT
Filing Type: 10-K
Importance Score:
8
AN2 Therapeutics Secures $40M Private Placement at Deep Discount, Reports Continued Internal Control Weaknesses
Sentiment: Negative
View Wiseek Article
ANTX
Mar 17, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
8
AN2 Therapeutics Reports Q4/FY25 Results, Extends Runway to 2029, Advances Multiple Phase 2 Programs
Sentiment: Positive
View Wiseek Article
ANTX
Mar 09, 2026, 9:43 PM EDT
Filing Type: 8-K
Importance Score:
9
AN2 Therapeutics Secures $40M Private Placement at Deep Discount, Significant Dilution Expected
Sentiment: Negative
View Wiseek Article
ANTX
Mar 03, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
7
AN2 Therapeutics Plans Phase 2 Study for Oral Epetraborole in Polycythemia Vera
Sentiment: Positive
View Wiseek Article